Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 5Terminated 4Withdrawn 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Terminated × Interventional × ostarine × Clear all
NCT01616758 2024-03-08

Phase II Study of GTx024 in Women With Metastatic Breast Cancer

GTx

Phase 2 Terminated
22 enrolled 5 charts
Breast

Breast Neoplasms

NCT05065411 2024-02-26

VERU-024

Veru Inc.

Phase 3 Terminated
5 enrolled
Breast

Breast Neoplasms

NCT04869943 2024-01-26

ARTEST

Veru Inc.

Phase 3 Terminated
52 enrolled
Breast

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

NCT02368691 2020-11-18

Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

GTx

Phase 2 Terminated
32 enrolled 12 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡